trh

Protirelin (Thyroliberin) is a tripeptide that stimulates the release of thyrotropin and prolactin.

Protirelin Acetate (TRH Acetate) is a thyrotropin-releasing hormone, stimulating the release of thyrotropin and prolactin from the anterior pituitary.

(Glu2)-TRH is a metabolically stable analogue of Thyrotropin-releasing hormone (TRH) that functions as a negative modulator of the cholinergic effects of TRH in the mouse brain. (Glu2)-TRH significantly reduces TRH-induced extracellular acetylcholine release in the hippocampus and demonstrates resistance to metabolism by thyroliberinase. (Glu2)-TRH additionally exhibits neuroprotective, antidepressant, and anticonvulsant properties in the central nervous system. (Glu2)-TRH is therefore valuable for neuropharmacology, neurotransmitter regulation, and central nervous system signaling research.

'[Phe2]-TRH, a thyrotropin-releasing hormone analogue, exhibits conformational similarity to Leu5-enkephalin [1].'

Prepro-TRH-(160-169), a connecting peptide of the thyrotropin-releasing hormone prohormone (pro-TRH), enhances TRH-induced thyrotropin (TSH) release [1].

TRH-glycine (TRH-gly) serves as a precursor to thyrotropin-releasing hormone (TRH), capable of inducing the release of thyrotropin (TSH) and prolactin [1].

Thyrotropin Releasing Hormone Precursor Peptide

TRH tartrate is a thyrotropin-releasing hormone.

Thyrotropin-Releasing Hormone (TRH), Free Acid (TRH-OH), induces various thyroidal and non-thyroidal effects, most notably the feedback regulation of thyroid hormone levels.

Pyroglutaminyl-seryl-leucinamide is a bioactive chemical.

Protirelin Acetate(24305-27-9 free base) (Thyroliberin Acetate) is a tripeptide that stimulates the release of thyrotropin and prolactin.

Taltirelin acetate (TA-0910 acetate) is a superagonist of the thyrotropin-releasing hormone receptor (TRH-R), with an IC50 of 910 nM and an EC50 of 36 nM for stimulating an increase in cytosolic Ca2+ concentration (Ca2+ release).

Taltirelin (TA-0910) is at thyrotropin-releasing hormone receptor (TRH-R) superagonist (IC50 of 910 nM and EC50 of 36 nM for stimulating an increase in cytosolic Ca2+ concentration (Ca2+ release))[1].

ATRHuman Pre-designed siRNA Set A consists of three siRNA pairs designed to target different regions of the ATR (Human) gene. The set also includes a negative control, a FAM-labeled negative control, and a positive control.

ent-Rhizocarpic acid is the enantiomer of Rhizocarpic acid. Compared to Rhizocarpic acid, ent-Rhizocarpic acid exhibits stronger antibacterial and antiparasitic properties against Staphylococcus aureus (ATCC 25923) and Giardia duodenalis 713. Additionally, ent-Rhizocarpic acid shows weak yet selective antitumor activity against NS-1 cells.

Azetirelin (YM 14673) is a new thyrotropin-releasing hormone (TRH) analog.

Rovatirelin (S-0373) is a newly synthesized thyrotropin-releasing hormone (TRH) analog that ameliorates cytosine arabinoside-induced motor dysfunction in a rat model of spinal cerebellar degeneration via acetylcholine and dopamine neurotransmission.

PGlu-3-methyl-His-Pro-NH2 TFA enhances binding to pituitary TRH receptors, thereby increasing the stimulation of thyroid-stimulating hormone (TSH) release from the pituitary.

Rovatirelin (also known as S-0373) is a novel synthetic compound that mimics the action of thyrotropin-releasing hormone (TRH). This compound exhibits a higher affinity for human TRH receptors (Ki=702nM) compared to taltirelin (Ki=3877nM). In acutely isolated norepinephrine neurons of the rat locus coeruleus (LC), rovatirelin enhances the firing of spontaneous action potentials. Additionally, rovatirelin increases motor activity and may offer potential therapeutic benefits as an oral treatment for patients with SCD.

Histidylprolineamide is the N-terminal of TRH.

MK771 is a therapeutic agent and an analog of the Thyrotropin Releasing Hormone (TRH). TRH and its analogs may be useful in combating some of the withdrawal symptoms in opiate-dependent subjects.

Thyrotropin-releasing hormone, deamido- is a biochemical.

S 17092 (S 17092-1) is a highly potent, reversible, and orally active small-molecule inhibitor of brain peptidylprolyl endopeptidase (PEP), with a binding constant (Ki) of 1.5 nM and an IC₅₀ of 1.2 nM against recombinant human PEP. By slowing the degradation of various neuroactive peptides, including Substance P, thyrotropin-releasing hormone (TRH), and arginine vasopressin (AVP), S 17092 increases the levels of these peptides in the brain and improves age-related or drug-induced memory and cognitive impairments in various rodent and primate animal models. S 17092 has been used in studies related to Alzheimer’s disease and cognitive impairment to evaluate the role of PEP regulation in neural function.

JKC363 TFA is a selective melanocortin MC4 receptor antagonist that exhibits a 90-fold higher affinity for the MC4 receptor (IC50=0.5 nM) compared to the MC3 receptor (44.9 nM). This compound effectively inhibits the α-MSH-induced stimulation of TRH release. It also demonstrates an anti-hyperalgesic effect [1] [2].